Literature DB >> 8344704

T-cell activation. VI. Inhibitory and stimulatory effects of anti-major histocompatibility complex class I antibodies in allogeneic mixed lymphocyte culture.

M Röpke1, C Röpke, M H Claësson.   

Abstract

Murine T splenocytes stimulated in primary allogeneic mixed lymphocyte culture (MLC) were incubated with soluble anti-major histocompatibility complex (MHC) class I monoclonal antibodies. These antibodies induced inhibition in the cytotoxicity of the responding population and this inhibition was not dependent on the domain on class I molecules recognized by the antibodies. Cross-reactivity of the antibodies between the responder and stimulating cell population caused a marked reduction in the inhibitory effect compared to systems where no such cross-reactivity was present. Saturating levels of the antibodies caused a reduction in generation of T-cell cytotoxicity, whereas low concentrations stimulated the same response. These results demonstrate that the MHC class I molecules of T cells are of significant importance in antigen-induced signal transduction.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8344704      PMCID: PMC1421874     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  36 in total

Review 1.  MHC-restricted cytotoxic T cells: studies on the biological role of polymorphic major transplantation antigens determining T-cell restriction-specificity, function, and responsiveness.

Authors:  R M Zinkernagel; P C Doherty
Journal:  Adv Immunol       Date:  1979       Impact factor: 3.543

2.  Influence of HLA class I- and class II-specific monoclonal antibodies on DR-restricted lymphoproliferative responses. I. Unseparated populations of effector cells.

Authors:  G Sterkers; Y Henin; J Kalil; M Bagot; J P Levy
Journal:  J Immunol       Date:  1983-12       Impact factor: 5.422

3.  Monoclonal antibodies to mouse major histocompatibility complex antigens.

Authors:  K Ozato; N M Mayer; D H Sachs
Journal:  Transplantation       Date:  1982-09       Impact factor: 4.939

4.  Two allelic forms of mouse beta 2-microglobulin.

Authors:  P J Robinson; L Graf; K Sege
Journal:  Proc Natl Acad Sci U S A       Date:  1981-02       Impact factor: 11.205

5.  Beta 2-microglobulin from serum associates with MHC class I antigens on the surface of cultured cells.

Authors:  C Bernabeu; M van de Rijn; P G Lerch; C P Terhorst
Journal:  Nature       Date:  1984 Apr 12-18       Impact factor: 49.962

6.  Influence of the mouse major histocompatibility complex, H-2, on liver adenylate cyclase activity and on glucagon binding to liver cell membranes.

Authors:  W Lafuse; M Edidin
Journal:  Biochemistry       Date:  1980-01-08       Impact factor: 3.162

7.  Striking paucity of HLA-A, B, C and beta 2-microglobulin on human neuroblastoma cell lines.

Authors:  L A Lampson; C A Fisher; J P Whelan
Journal:  J Immunol       Date:  1983-05       Impact factor: 5.422

8.  Paired H-2-specific monoclonal antibodies react differently to red cells and lymphocytes.

Authors:  S L Tonkonogy; D B Amos
Journal:  Immunogenetics       Date:  1981-12       Impact factor: 2.846

9.  Monoclonal antibodies to mouse MHC antigens. III. Hybridoma antibodies reacting to antigens of the H-2b haplotype reveal genetic control of isotype expression.

Authors:  K Ozato; D H Sachs
Journal:  J Immunol       Date:  1981-01       Impact factor: 5.422

10.  Interaction between major histocompatibility complex antigens and epidermal growth factor receptors on human cells.

Authors:  A B Schreiber; J Schlessinger; M Edidin
Journal:  J Cell Biol       Date:  1984-02       Impact factor: 10.539

View more
  1 in total

1.  Ligation of major histocompatability complex (MHC) class I molecules on human T cells induces cell death through PI-3 kinase-induced c-Jun NH2-terminal kinase activity: a novel apoptotic pathway distinct from Fas-induced apoptosis.

Authors:  S Skov; P Klausen; M H Claesson
Journal:  J Cell Biol       Date:  1997-12-15       Impact factor: 10.539

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.